-
Firefly Luciferase mRNA for Translational Benchmarking
2026-08-28
A thought-leadership guide to using Cap1, 5-moUTP, and poly(A) design to build more interpretable mRNA delivery studies. The article connects reporter expression with sex-aware preclinical study design and shows how EZ Cap™ Firefly Luciferase mRNA (5-moUTP) can support rigorous translational benchmarking without overinterpreting luminescence as an immune or therapeutic endpoint.
-
Amikacin disulfate: Assays, Workflows & Troubleshooting
2026-08-28
Use Amikacin disulfate to connect bacterial ribosome experiments with protein-binding, fluorescence, and resistance workflows. This practical guide covers fresh-solution handling, assay design, reference-study insights, and troubleshooting strategies for more interpretable results.
-
AO/PI Double Staining Kit: Practical Cell Viability Guide
2026-08-27
The AO/PI Double Staining Kit provides a rapid fluorescent cell staining workflow for distinguishing viable, apoptotic, and necrotic cell populations in one sample. It is suitable for cell viability screening and comparative experiments, but it should not be treated as a standalone confirmation of a specific cell-death pathway or used without sample- and instrument-specific validation.
-
Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5
2026-08-27
A practical, scenario-based guide to using Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 (SKU K1188) for acid mucin detection, chondrogenic differentiation, and morphology assessment. It explains assay compatibility, workflow controls, interpretation limits, storage, and vendor-selection considerations for research laboratories.
-
Romidepsin (FK228) in HCC Splicing Research
2026-08-26
Romidepsin (FK228) offers a practical way to connect class I HDAC inhibition with chromatin state, SmD2 regulation, alternative splicing, and PARP-inhibitor response. This workflow translates the reference study into dose-response, acetylation, splice-junction, and combination assays while separating established evidence from pilot optimization.
-
Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro
2026-08-26
The reference study used an enzymatic high-throughput screen of approximately 6,000 compounds to identify Merbromin as a selective inhibitor of the SARS-CoV-2 3CLpro protease. Kinetic, binding, and docking analyses support a mixed-type inhibition model involving two putative binding sites, while comparison with Proteinase K, trypsin, and papain indicates meaningful protease selectivity.
-
Novobiocin Susceptibility in Canine Staphylococci
2026-08-25
This study compared in vitro susceptibility to novobiocin and mupirocin among meticillin-susceptible and meticillin-resistant staphylococci from healthy dogs and dogs with superficial pyoderma. Its main contribution is a clinically relevant isolate-level comparison showing strong novobiocin activity against most susceptible isolates, but substantially more variable activity against resistant populations.
-
WZ4003 Lowers Tau p-Ser356 in Brain Tissue
2026-08-25
Taylor et al. characterized tau phosphorylation at Ser356 as an Alzheimer’s disease-associated pathology and tested the NUAK1/2 inhibitor WZ4003 in mouse and human brain slice cultures. The study’s most important translational insight is that NUAK inhibition lowered p-tau Ser356 in human tissue, while mouse slices showed broader changes in tau and neuronal proteins that require careful interpretation.
-
Proteinase K as a Protease Mapping Tool
2026-08-24
Proteinase K is more than a DNA-cleanup reagent: it can serve as a controlled protease probe for distinguishing extracellular-vesicle surface proteins from protected cargo. This article connects Proteinase K chemistry with recent Candida albicans EV research and shows how to design interpretable mechanistic assays.
-
SW033291: 15-PGDH Inhibitor Workflow
2026-08-24
SW033291 is a potent 15-PGDH inhibitor for connecting enzyme blockade with prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue repair readouts. This practical workflow separates biochemical potency from cell and marrow phenotypes while clarifying how recent muscle-regeneration findings can guide, but not replace, SW033291-specific validation.
-
Vancomycin Hydrochloride as a Resistance Benchmark
2026-08-23
Vancomycin hydrochloride is more than a familiar antimicrobial reagent: it is a mechanistically defined benchmark for Gram-positive bacteria inhibition, bacterial susceptibility testing, and antibiotic resistance assay design. This article connects its D-alanyl-D-alanine targeting mechanism with time-resolved resistance analysis, translational infection models, and the semi-mechanistic PKPD framework used to dissect ceftolozane/tazobactam resistance in Pseudomonas aeruginosa.
-
Spatial Proteomics Maps PD-L1–IL-6 Crosstalk in PSC
2026-08-22
A recent JHEP Reports study integrates spatial proteomics with cell-cell cross-talk analysis to identify a spatially organized relationship between PD-L1 and IL-6 signaling in human primary sclerosing cholangitis. The work links immune-checkpoint biology with cytokine activity at the biliary epithelial–immune interface and provides a rationale for mechanism-focused follow-up studies.
-
5-Methyl-CTP for Translational mRNA Design
2026-08-22
5-Methyl-CTP enables controlled incorporation of methylated cytidine during mRNA synthesis with modified nucleotides. This article connects transcript chemistry to delivery, antigen presentation, and practical assay design for mRNA drug development.
-
MTT Workflow for Mitochondrial Rescue Studies
2026-08-21
Learn how to use MTT to quantify cardiomyocyte metabolic recovery, compare sequential treatment schedules, and troubleshoot assay artifacts after ischemia-reperfusion modeling. The workflow connects a practical colorimetric endpoint with the sequential mitochondrial transplantation strategy described in recent myocardial injury research.
-
CBX2, Interferon Signaling, and Tumor Immunogenicity
2026-08-20
The reference study identifies a noncanonical CBX2–RACK1–HDAC1 corepressor complex that represses interferon-stimulated genes and reduces tumor immunogenicity independently of canonical PRC activity. Its results connect CBX2 abundance with an immune-suppressive tumor microenvironment and weaker immunotherapy responses, while suggesting experimental strategies for studying epigenetic control of antitumor immunity.